Final quarter of FY08 down again, year the worst on record: PwC

BIO 2008, the world's largest conference for the biotechnology industry, is being held in San Diego from June 16. In our annual preview, we take a look at how the Australian sector is travelling.

Biotechs crunchy, Mesoblast keen, LabTech launches and NeuroDiscovery averts pain.

Adelaide biotechs vivoPharm and TGR expand and contract.

With AusBiotech 2007 being held in Brisbane next week, ALS takes its bi-annual survey of the state of the industry.

Pharma market to double in value but more needs to be spent on R&D and less on sales and marketing - PwC report.

Last year wasn't the best on record for the Australian biotechnology industry but this year and the next look much more promising. Share prices are up, investors are showing more interest and there are a lot of good stories to tell and sell.

It hasn't been the best year on record for the Australian biotechnology industry but things should improve somewhat next year. Kate McDonald reports that the fragility of the sector is sure to be a topic of discussion at this year's AusBiotech conference.

The value of the Australian life science sector declined 3.5 per cent during the fourth quarter, ending 30 June 2006, according to the latest BioForum report from PricewaterhouseCoopers (PwC).

The Australian life sciences sector has picked up with small cap stocks seeing positive growth in the last quarter, according to the November edition of PricewaterhouseCoopers' quarterly BioForum report.

The latest edition of PricewaterhouseCoopers' quarterly BioForum report is published today, and shows a second consecutive decline in Australian life science stocks in Q4 of the 2004-05 financial year.